Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Hodgkin Disease 8Lymphoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Mycosis Fungoides 1Lymphomatoid Papulosis 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Primary Cutaneous Anaplastic Large Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphatic Diseases 1Leukemia 1Immunoblastic Lymphadenopathy 1Hematologic Diseases 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

prednylidene 1pembrolizumab 1etoposide phosphate 1deltacortene 1Prednisone 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Cholecalciferol 1Brentuximab Vedotin 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Enteropathy-Associated T-Cell Lymphoma × Brentuximab Vedotin × Clear all
NCT03113500 2025-11-14

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

City of Hope Medical Center

Phase 2 Active not recruiting
48 enrolled 8 charts
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡